Kenneda v. United States

815 F. Supp. 926, 1993 U.S. Dist. LEXIS 3516, 1993 WL 73704
CourtDistrict Court, S.D. West Virginia
DecidedMarch 11, 1993
DocketCiv. A. 1:87-0912
StatusPublished
Cited by3 cases

This text of 815 F. Supp. 926 (Kenneda v. United States) is published on Counsel Stack Legal Research, covering District Court, S.D. West Virginia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Kenneda v. United States, 815 F. Supp. 926, 1993 U.S. Dist. LEXIS 3516, 1993 WL 73704 (S.D.W. Va. 1993).

Opinion

MEMORANDUM OPINION, FINDINGS OF FACT AND CONCLUSIONS OF LAW

FABER, District Judge.

On August 11,1987, plaintiff Linda Kenneda filed this action pursuant to the Federal Tort Claims Act, 28 U.S.C. §§ 1346(b), 2671, et seq., and the National Swine Flu Immunization Program of 1976, 42 U.S.C. § 248b, alleging that she had developed GuillainBarre Syndrome as a result of a swine flu vaccine administered to her in Princeton, West Virginia, on November 19, 1976. The United States asserts that plaintiffs illness is not Guillain-Barre Syndrome and that it is unrelated to the swine flu vaccine.

This action was originally transferred by the Judicial Panel on Multidistrict Litigation to the United States District Court for the District of Columbia for coordinated pretrial proceedings, In re Swine Flu Immunization Products Liability Litigation, 89 F.R.D. 695 (D.D.C.1980), pursuant to 28 U.S.C. § 1407. The district court subsequently dismissed the complaint on the ground that the plaintiff had not filed her administrative claim within two years from the time her cause of action accrued as required by 28 U.S.C. § 2401(b). The dismissal was appealed, the judgment of *928 the district court was reversed and the case was remanded for further proceedings. In re Swine Flu Immunization Products Liability Litigation, Kenneda v. United States, 880 F.2d 1439 (D.C.Cir.1989). A conditional remand order was entered on February 13, 1990, and the case was officially reinstated on the active docket of this court on April 4, 1990.

A joint motion for separate trials on liability and damages was granted by Order dated April 7, 1992. A non-jury trial was held on liability on May 12-13, 1992. Although causation was vigorously contested, the United States stipulated that the plaintiff need not prove a theory of liability. Therefore, the only issue presently before this court is causation.

Findings of Fact

1. The Swine Flu Program was enacted into law by Congress and the President in 1976 on an emergency basis in an effort to avoid a potential flu epidemic. The parties stipulated that the plaintiff Linda Kenneda received a swine flu vaccination at the Mercer County Health Care Clinic, Princeton, West Virginia, on November 19, 1976, and the court so finds.

2.. Guillain-Barre Syndrome is a set of symptoms occurring together that primarily affect the peripheral nervous system. The peripheral nervous system is the portion of the nervous system which consists of nerves outside the brain and spinal cord, as opposed to the central nervous system, which consists of the brain and spinal cord. Guillain-Barre Syndrome has been described in a set of diagnostic criteria prepared by the National Institute of Neurological and Communicative Disorders and Stroke (hereinafter NINCDS).

3.Two principal symptoms characterize Guillain-Barre Syndrome, and the NINCDS criteria have identified each of these symptoms as required for diagnosis. The first is progressive motor weakness of more than one limb. This weakness can range from minimal weakness to total paralysis. The weakness most commonly begins in the lower extremities and ascends to the upper limbs. Usually the weakness is symmetrical. The second symptom required for diagnosis is a loss of reflexes, referred to as areflexia. The loss of reflexes need not be complete but some loss of reflexes is essential for diagnosis.

4. A prominent feature of Guillain-Barre Syndrome is a rapidly progressive paralysis which occurs over a relatively short period of time, usually peaking between the third and fourth week, followed by a stabilized period which is, in turn, followed by a period of recovery. The progression of the weakness is usually completed within three weeks. Ninety percent of the Guillain-Barre Syndrome patients will have stopped progressing after four weeks. Most patients recover completely. Some, however, may continue to have residual neurological deficits.

5. The exact cause of Guillain-Barre Syndrome is unknown. It is thought to be an inflammatory reaction to a foreign antigen. The introduction of the foreign antigen is thought to stimulate an autoimmune reaction which causes the body to attack itself. This reaction eventually causes the destruction of insulation around the nerves causing them to become dysfunctional. This process is known as demyelination.

6. Guillain-Barre Syndrome has been associated with a number of antecedent events. Those events include, but are not limited to, anesthesia, surgery, malignancy, vaccination, and viral infection. The most common antecedent event is a viral infection. In fact, fifty to sixty percent of all patients diagnosed with Guillain-Barre Syndrome describe an antecedent nonspecific viral illness, such as an upper respiratory infection or gastrointestinal illness.

7. Guillain-Barre Syndrome has also been associated with the administration of the swine flu vaccine. The evidence of a causal relationship between Guillain-Barre Syndrome and swine flu vaccine is epidemiological, or statistical. A study conducted by Dr. Lawrence Schonberger and reported in, Guillain Barre Syndrome Following Vaccination in the National Influenza Immunization Program, United States, 1976-1977, 110 Am.J. of Epidemiol. 105 (1979), analyzed and compared the Guillain-Barre Syndrome attack rates in both the vaccinated and unvac *929 cinated populations of the United States. Schonberger utilized the NINCDS criteria for the identification of cases of GuillainBarre Syndrome. The study found that the incidence of Guillain-Barre Syndrome increased significantly above the expected or normal rate after administration of the swine flu vaccination in 1976 and 1977. The study established that the largest percentage of vaccine-related Guillain-Barre Syndrome cases occurred in the second to third weeks following vaccination. The study further found no causal relationship between Guillain-Barre Syndrome and swine flu vaccination beyond ten weeks from the date of vaccination.

8. The plaintiff Linda Kenneda was born on February 2,1947. The plaintiff is a woman of limited education and intellect, having completed the third grade of elementary school and having a full-scale I.Q. score on testing of approximately 72.

9. The plaintiff received a swine flu inoculation from the Mercer County Health Care Center in Princeton, West Virginia, on November 19, 1976. On that date, the Mercer County Health Care Center was acting as a “program participant” for the National Swine Flu Immunization Program.

10. At trial, plaintiff testified that on the evening she received the swine flu shot she became ill and vomited. By the third day following the shot, plaintiff testified that she felt better, but, by December .1976, she began to feel weakness, numbness and pain in her hands and feet.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Johnson
122 F. Supp. 3d 272 (M.D. North Carolina, 2015)

Cite This Page — Counsel Stack

Bluebook (online)
815 F. Supp. 926, 1993 U.S. Dist. LEXIS 3516, 1993 WL 73704, Counsel Stack Legal Research, https://law.counselstack.com/opinion/kenneda-v-united-states-wvsd-1993.